> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Changes Date of Endocrinologic/Metabolic Drugs Panel Meeting
- URL: https://www.fdaweb.com/fda-changes-date-of-endocrinologic-metabolic-drugs-panel-meeting/
- Published: 2016-04-06T12:00:00.000Z
- Updated: 2026-09-14T20:53:08.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5135297

*Federal Register* Notice: FDA is amending the notice of a meeting of the Endocrinologic and Metabolic Drugs Advisory Committee to reflect a change in date to 5/25 from 8 a.m. to 5 p.m. This meeting was announced in the 3/16 *Federal Register* and is scheduled to discuss Sanofi-aventis NDAs for insulin glargine and lixisenatide injection, a fixed ratio drug product consisting of insulin and a GLP-1 receptor agonist, and 208471 for lixisenatide injection, a GLP-1 receptor agonist proposed for treating adults with Type 2 diabetes mellitus. Contact **LaToya Bonner**, (301) 796-9001 or Latoya.Bonner@fda.hhs.gov. To view this notice, click [here.](https://www.gpo.gov/fdsys/pkg/FR-2016-04-06/pdf/2016-07899.pdf?ref=fdaweb.com)